Applications of Multivariate Data Analysis in Biotech Processing - - BioPharm International

ADVERTISEMENT

Applications of Multivariate Data Analysis in Biotech Processing


BioPharm International
Volume 20, Issue 10


Table 1A. Parameter estimates for data presented in Figure 2.
Expert bias exists in the selection of initial factors to include in the model, but this bias is often constrained to a set of actionable parameters, which can be addressed on the production floor to mitigate unexpected process behavior. The inclusion of nonactionable factors in the model, such as maximum lactate production or initial glucose uptake rate, yields scientifically relevant ideas for further investigation, but is not as useful for immediately improving production culture performance and achieving production campaign targets. Actionable process parameters were studied from 25 batches of campaign 2 of this antibody process and were used to build the model shown in Figure 2, Table 1A, and Table 1B.


Table 1B. Scaled estimates for data presented in Figure 2.
We know from our historical experience that models with an adjusted R 2 of 0.76 and the root mean square error (RMSE)of 91 are capable of supporting data-based decisions. The linear equation was solved to determine the magnitude and direction of parameter change necessary to maximize culture performance.


Figure 3. The model generates the direction and magnitude for each factor in order to maximize production culture performance and minimize a product quality attribute.
We re-optimized the parameters to maximize culture productivity and minimize a product quality attribute (in this case with a maximum but no minimum specification). The model achieved an optimum and prescribed specific targets for these parameters.

Figure 3 indicates the actions required to achieve this optimum:
  • Increase initial concentration of a production culture parameter
  • Decrease the time at which culture operation 1 occurs
  • Increase the time at which culture operation 2 occurs
  • Increase the time at which culture operation 3 occurs
  • Decrease the set point of operating parameter 1.

The parameter changes were implemented incrementally and thus resulted in a gradual improvement in culture productivity.


Figure 4. Performance of campaign 3 shows initial lower-than-expected productivity that was overcome by process parameter changes. The variability of culture performance was 25% RSD.
Figure 4 demonstrates the gradual improvement in culture performance during campaign 3, which ultimately resulted in production of 104% of the campaign goal. While campaign 3 of this antibody process met goals through incremental parameter changes, the process variability was unacceptably large at 25% relative standard deviation (RSD). For the fourth campaign, the process parameters were evaluated and targets were reset with capability in mind. Most parameters remain changed in the direction prescribed by the MLR, but the magnitude decreased in order to maintain capability and minimize process variability.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here